LRRK2 inhibitors may combat Parkinson's progression
the Psychiatry Advisor take:
An enzyme closely associated with genetic forms of Parkinson's disease appears to play a larger role in its progression than previously thought, say investigators at the University of Alabama at Birmingham.
"We found that this offered very good protection from over-expression of a protein -- alpha synuclein -- that is linked to Parkinson's disease," said Andrew West, PhD, lead author on the paper and the John A. and Ruth R. Jurenko Endowed Professor in Neurology at UAB.
The genetic model used in the UAB study more closely mimics Parkinson's disease than do other, more frequently used models, which suggests that inhibiting LRRK2 in humans could help more than those with the less-common genetic forms.
"The pool of Parkinson's patients who might benefit from LRRK2 drugs may be bigger than we originally thought," West said.
LRRK2 inhibitors may be key to combating parkinson's disease
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Sertraline Effective for Treating Depression in Vascular Cognitive Impairment
- Hospitalization Rates in Schizophrenia—Lurasidone vs Quetiapine
- Ketamine-Induced Dissociative Symptoms Predict Antidepressant Response
- First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Review Examines the Effectiveness of Antidepressants for Insomnia
- Video Games and Exercise as Alternative Therapies for ADHD
- How Parents Can Enhance Autism Treatment: Use of Intervention Strategies at Home
- Electroconvulsive Therapy Effective in Children With Autism
- Comorbid Autism Spectrum Disorder and OCD: Challenges in Diagnosis and Treatment
- The Cutting Edge of Schizophrenia Research: VR as Treatment for Psychosis
- Antidepressant Use May Be Linked With Sustained Risk for Weight Gain
- Language Used in Medical Record Can Affect Patient Care
- Family History of Psychiatric Disorders an Important Predictor of Postpartum Psychiatric Illness
- Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD
- Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV